Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

6. November 2026 aktualisiert von: Novartis Pharmaceuticals

Eine randomisierte, doppelblinde Doppel-Dummy-Parallelgruppenstudie zum Vergleich der Wirksamkeit und Sicherheit von Remibrutinib gegenüber Teriflunomid bei Teilnehmern mit schubförmiger Multipler Sklerose, gefolgt von einer verlängerten Behandlung mit unverblindetem Remibrutinib

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.

The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).

The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.

A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

1007

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Buenos Aires, Argentinien, C1012AAR
        • Novartis Investigative Site
      • CABA, Argentinien, C1181ACH
        • Novartis Investigative Site
      • Córdoba, Argentinien, X5004CDT
        • Novartis Investigative Site
    • Mendoza Province
      • Bombal, Mendoza Province, Argentinien, M5500DXO
        • Novartis Investigative Site
    • Santa Fe Province
      • Rosario, Santa Fe Province, Argentinien, S2000BZL
        • Novartis Investigative Site
      • Rosario, Santa Fe Province, Argentinien, S2000DSW
        • Novartis Investigative Site
    • Tucumán Province
      • San Miguel de, Tucumán Province, Argentinien, T4000
        • Novartis Investigative Site
      • São Paulo, Brasilien, 01240-020
        • Novartis Investigative Site
    • Espírito Santo
      • Vitória, Espírito Santo, Brasilien, 29055-450
        • Novartis Investigative Site
    • Federal District
      • Brasília, Federal District, Brasilien, 70200-730
        • Novartis Investigative Site
    • Paraná
      • Curitiba, Paraná, Brasilien, 81210-310
        • Novartis Investigative Site
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90430-001
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90560-032
        • Novartis Investigative Site
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90620-130
        • Novartis Investigative Site
    • Santa Catarina
      • Joinville, Santa Catarina, Brasilien, 89202-165
        • Novartis Investigative Site
      • Plovdiv, Bulgarien, 4002
        • Novartis Investigative Site
      • Sofia, Bulgarien, 1309
        • Novartis Investigative Site
      • Sofia, Bulgarien, 1431
        • Novartis Investigative Site
      • Sofia, Bulgarien, 1407
        • Novartis Investigative Site
      • Beijing, China, 100034
        • Novartis Investigative Site
      • Shanghai, China, 200025
        • Novartis Investigative Site
      • Shanghai, China, 200040
        • Novartis Investigative Site
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Novartis Investigative Site
      • Wuhan, Hubei, China, 430060
        • Novartis Investigative Site
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Novartis Investigative Site
    • Ningxia
      • Yinchuan, Ningxia, China, 750004
        • Novartis Investigative Site
    • Shanxi
      • Taiyuan, Shanxi, China, 030001
        • Novartis Investigative Site
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310016
        • Novartis Investigative Site
      • Hangzhou, Zhejiang, China, 310006
        • Novartis Investigative Site
      • Wenzhou, Zhejiang, China, 325000
        • Novartis Investigative Site
      • Essen, Deutschland, 45147
        • Novartis Investigative Site
      • Hamburg, Deutschland, 22179
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Freiburg im Breisgau, Baden-Wurttemberg, Deutschland, 79106
        • Novartis Investigative Site
      • Tallinn, Estland, 11315
        • Novartis Investigative Site
      • Tartu, Estland, 50406
        • Novartis Investigative Site
      • Caen, Frankreich, 14033
        • Novartis Investigative Site
      • Clermont-Ferrand, Frankreich, 63003
        • Novartis Investigative Site
      • Dijon, Frankreich, 21000
        • Novartis Investigative Site
      • Gonesse, Frankreich, 95500
        • Novartis Investigative Site
      • Grenoble, Frankreich, 38043
        • Novartis Investigative Site
      • Lille, Frankreich, 59037
        • Novartis Investigative Site
      • Lille, Frankreich, 59000
        • Novartis Investigative Site
      • Nice, Frankreich, 06000
        • Novartis Investigative Site
      • Nîmes, Frankreich, 30029
        • Novartis Investigative Site
      • Poissy, Frankreich, 78303
        • Novartis Investigative Site
      • Toulouse, Frankreich, 31059
        • Novartis Investigative Site
    • Haute Vienne
      • Limoges, Haute Vienne, Frankreich, 87000
        • Novartis Investigative Site
    • Val De Marne
      • Toulon, Val De Marne, Frankreich, 83800
        • Novartis Investigative Site
      • Athens, Griechenland, 115 28
        • Novartis Investigative Site
      • Athens, Griechenland, 115 26
        • Novartis Investigative Site
      • Chaïdári, Griechenland, 124 62
        • Novartis Investigative Site
      • Ioannina, Griechenland, 455 00
        • Novartis Investigative Site
      • Larissa, Griechenland, 411 10
        • Novartis Investigative Site
      • Thessaloniki, Griechenland, 532 46
        • Novartis Investigative Site
      • Thessaloniki, Griechenland, 546 36
        • Novartis Investigative Site
    • Kerala
      • Kochi, Kerala, Indien, 682025
        • Novartis Investigative Site
    • Maharashtra
      • Pune, Maharashtra, Indien, 411013
        • Novartis Investigative Site
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, Indien, 110060
        • Novartis Investigative Site
    • Punjab
      • Amritsar, Punjab, Indien, 143006
        • Novartis Investigative Site
    • Telangana
      • Hyderabad, Telangana, Indien, 500082
        • Novartis Investigative Site
    • Uttar Pradesh
      • Lucknow, Uttar Pradesh, Indien, 226007
        • Novartis Investigative Site
    • West Bengal
      • Kolkata, West Bengal, Indien, 700017
        • Novartis Investigative Site
      • Naples, Italien, 80138
        • Novartis Investigative Site
    • BR
      • Brindisi, BR, Italien, 72100
        • Novartis Investigative Site
    • FG
      • Foggia, FG, Italien, 71122
        • Novartis Investigative Site
    • IS
      • Pozzilli, IS, Italien, 86077
        • Novartis Investigative Site
    • ME
      • Messina, ME, Italien, 98124
        • Novartis Investigative Site
    • MO
      • Modena, MO, Italien, 41126
        • Novartis Investigative Site
    • PV
      • Pavia, PV, Italien, 27100
        • Novartis Investigative Site
    • TO
      • Orbassano, TO, Italien, 10043
        • Novartis Investigative Site
      • Fukuoka, Japan, 8128582
        • Novartis Investigative Site
      • Niigata, Japan, 9518520
        • Novartis Investigative Site
    • Aichi-ken
      • Nagoya, Aichi-ken, Japan, 4668560
        • Novartis Investigative Site
    • Chiba
      • Chiba, Chiba, Japan, 2608677
        • Novartis Investigative Site
      • Ichihara, Chiba, Japan, 2990111
        • Novartis Investigative Site
    • Fukuoka
      • Fukuoka, Fukuoka, Japan, 8100022
        • Novartis Investigative Site
    • Hokkaido
      • Sapporo, Hokkaido, Japan, 0630005
        • Novartis Investigative Site
    • Hyōgo
      • Kobe, Hyōgo, Japan, 6500017
        • Novartis Investigative Site
      • Nishinomiya, Hyōgo, Japan, 663 8501
        • Novartis Investigative Site
    • Kanagawa
      • Isehara, Kanagawa, Japan, 2591193
        • Novartis Investigative Site
      • Sagamihara, Kanagawa, Japan, 2520375
        • Novartis Investigative Site
    • Kyoto
      • Kyoto, Kyoto, Japan, 6168255
        • Novartis Investigative Site
    • Miyagi
      • Sendai, Miyagi, Japan, 9838512
        • Novartis Investigative Site
    • Nara
      • Kashihara, Nara, Japan, 6348522
        • Novartis Investigative Site
    • Osaka
      • Moriguchi, Osaka, Japan, 5708507
        • Novartis Investigative Site
      • Suita, Osaka, Japan, 5650871
        • Novartis Investigative Site
    • Saitama
      • Higashi-Matsuyama, Saitama, Japan, 3550005
        • Novartis Investigative Site
    • Tokyo
      • Kodaira, Tokyo, Japan, 1878551
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japan, 1628666
        • Novartis Investigative Site
      • Shinjuku Ku, Tokyo, Japan, 1600023
        • Novartis Investigative Site
      • Shinjuku-ku, Tokyo, Japan, 1608582
        • Novartis Investigative Site
      • tabashi City, Tokyo, Japan, 1738610
        • Novartis Investigative Site
    • Alberta
      • Edmonton, Alberta, Kanada, T6G 2B7
        • Novartis Investigative Site
    • British Columbia
      • Burnaby, British Columbia, Kanada, V5G 2X6
        • Novartis Investigative Site
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 4K4
        • Novartis Investigative Site
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
        • Novartis Investigative Site
    • Quebec
      • Lévis, Quebec, Kanada, G6W 0M5
        • Novartis Investigative Site
      • Montreal, Quebec, Kanada, H4A 3T2
        • Novartis Investigative Site
      • Québec, Quebec, Kanada, G1J 1Z4
        • Novartis Investigative Site
      • Saint-Jérôme, Quebec, Kanada, J7Z 5T3
        • Novartis Investigative Site
      • Zagreb, Kroatien, 10000
        • Novartis Investigative Site
    • Croatia
      • Zagreb, Croatia, Kroatien, 10000
        • Novartis Investigative Site
    • HRV
      • Split, HRV, Kroatien, 21000
        • Novartis Investigative Site
      • Varaždin, HRV, Kroatien, 42000
        • Novartis Investigative Site
    • Vukovar
      • Vukovar, Vukovar, Kroatien, 32000
        • Novartis Investigative Site
      • Mexico City, Mexiko, 14050
        • Novartis Investigative Site
      • Querétaro, Mexiko, 76070
        • Novartis Investigative Site
    • Chihuahua
      • Chihuahua City, Chihuahua, Mexiko, 31203
        • Novartis Investigative Site
    • Mexico City
      • Mexico City, Mexico City, Mexiko, 06700
        • Novartis Investigative Site
      • Bialystok, Polen, 15-704
        • Novartis Investigative Site
      • Glogow Wielkopolski, Polen, 36-060
        • Novartis Investigative Site
      • Katowice, Polen, 40-081
        • Novartis Investigative Site
      • Katowice, Polen, 40-571
        • Novartis Investigative Site
      • Katowice, Polen, 40-686
        • Novartis Investigative Site
      • Katowice, Polen, 40-689
        • Novartis Investigative Site
      • Lublin, Polen, 20-701
        • Novartis Investigative Site
      • Wroclaw, Polen, 51-685
        • Novartis Investigative Site
      • Zabrze, Polen, 41-800
        • Novartis Investigative Site
    • Poznan
      • Plewiska, Poznan, Polen, 62-064
        • Novartis Investigative Site
      • Braga, Portugal, 4710-243
        • Novartis Investigative Site
      • Coimbra, Portugal, 3004-561
        • Novartis Investigative Site
      • Leiria, Portugal, 2410-197
        • Novartis Investigative Site
      • Lisbon, Portugal, 1649-035
        • Novartis Investigative Site
      • Lisbon, Portugal, 1169-050
        • Novartis Investigative Site
      • Matosinhos Municipality, Portugal, 4454-513
        • Novartis Investigative Site
      • Santa Maria da Feira, Portugal, 4520-211
        • Novartis Investigative Site
      • Guaynabo, Puerto Rico, 00968
        • Caribbean Center for Clinical Research Inc
      • Campulung Muscel, Rumänien, 115100
        • Novartis Investigative Site
      • Constanța, Rumänien, 900591
        • Novartis Investigative Site
    • ROM
      • Brasov, ROM, Rumänien, 500123
        • Novartis Investigative Site
      • Constanța, ROM, Rumänien, 900123
        • Novartis Investigative Site
      • Stockholm, Schweden, 102 35
        • Novartis Investigative Site
      • Banská Bystrica, Slowakei, 975 17
        • Novartis Investigative Site
      • Banská Bystrica, Slowakei, 974 04
        • Novartis Investigative Site
      • Bratislava, Slowakei, 833 05
        • Novartis Investigative Site
      • Celje, Slowenien, 3000
        • Novartis Investigative Site
      • Ljubljana, Slowenien, 1000
        • Novartis Investigative Site
    • Slovenia
      • Maribor, Slovenia, Slowenien, 2000
        • Novartis Investigative Site
      • Lleida, Spanien, 25198
        • Novartis Investigative Site
      • Madrid, Spanien, 28040
        • Novartis Investigative Site
      • Madrid, Spanien, 28009
        • Novartis Investigative Site
      • Málaga, Spanien, 29016
        • Novartis Investigative Site
      • Seville, Spanien, 41009
        • Novartis Investigative Site
      • Valencia, Spanien, 46026
        • Novartis Investigative Site
    • A Coruna
      • Santiago Compostela, A Coruna, Spanien, 15706
        • Novartis Investigative Site
    • Araba
      • Vitoria-Gasteiz, Araba, Spanien, 01009
        • Novartis Investigative Site
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Spanien, 08907
        • Novartis Investigative Site
    • Castille-La Mancha
      • Albacete, Castille-La Mancha, Spanien, 02006
        • Novartis Investigative Site
    • Catalonia
      • Barcelona, Catalonia, Spanien, 08003
        • Novartis Investigative Site
    • La Rioja
      • Logroño, La Rioja, Spanien, 26006
        • Novartis Investigative Site
    • Madrid
      • Pozuelo de Alarcón, Madrid, Spanien, 28223
        • Novartis Investigative Site
      • Torrejón de Ardoz, Madrid, Spanien, 28850
        • Novartis Investigative Site
    • Principality of Asturias
      • Gijón, Principality of Asturias, Spanien, 33394
        • Novartis Investigative Site
    • Valencia
      • Valencia, Valencia, Spanien, 46017
        • Novartis Investigative Site
      • Pretoria, Südafrika, 0041
        • Novartis Investigative Site
      • Rosebank, Südafrika, 2196
        • Novartis Investigative Site
    • Free State
      • Bloemfontein, Free State, Südafrika, 9301
        • Novartis Investigative Site
      • Brno, Tschechien, 602 00
        • Novartis Investigative Site
      • Hradec Králové, Tschechien, 500 05
        • Novartis Investigative Site
      • Teplice, Tschechien, 415 29
        • Novartis Investigative Site
      • Konya, Türkei (türkiye), 42130
        • Novartis Investigative Site
    • Atakum
      • Samsun, Atakum, Türkei (türkiye), 55200
        • Novartis Investigative Site
    • Balcova
      • Izmir, Balcova, Türkei (türkiye), 35340
        • Novartis Investigative Site
    • Fatih
      • Istanbul, Fatih, Türkei (türkiye), 34098
        • Novartis Investigative Site
      • Istanbul, Fatih, Türkei (türkiye), 34093
        • Novartis Investigative Site
    • Karabaglar
      • Izmir, Karabaglar, Türkei (türkiye), 35150
        • Novartis Investigative Site
    • Kocaeli
      • Köseköy, Kocaeli, Türkei (türkiye), 41380
        • Novartis Investigative Site
    • Melikgazi
      • Kayseri, Melikgazi, Türkei (türkiye), 38039
        • Novartis Investigative Site
    • Nilufer
      • Bursa, Nilufer, Türkei (türkiye), 16140
        • Novartis Investigative Site
    • Pendik
      • Istanbul, Pendik, Türkei (türkiye), 34899
        • Novartis Investigative Site
    • Sancaktepe
      • Istanbul, Sancaktepe, Türkei (türkiye), 34785
        • Novartis Investigative Site
    • Arizona
      • Phoenix, Arizona, Vereinigte Staaten, 85018
        • Ctr for Neurology and Spine
    • California
      • Hanford, California, Vereinigte Staaten, 93230
        • Vladimir Royter MD APMC
      • Los Angeles, California, Vereinigte Staaten, 90073
        • VA Greater LA Healthcare System
      • West Hollywood, California, Vereinigte Staaten, 90048
        • Regina Berkovich MD PhD Inc
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • CU Anschutz Med Campus
      • Denver, Colorado, Vereinigte Staaten, 80210
        • Colorado Neurological Research PC
    • Connecticut
      • Stamford, Connecticut, Vereinigte Staaten, 06905
        • New England Institute for Clinical Research
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20007
        • Georgetown University Hospital
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20007
        • Georgetown University Hospital Research
    • Florida
      • Bradenton, Florida, Vereinigte Staaten, 34209
        • Nova Clinical Research LLC
      • Gainesville, Florida, Vereinigte Staaten, 32610
        • University of Florida
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • Memorial Healthcare System
      • Maitland, Florida, Vereinigte Staaten, 32751
        • Neurology Associates PA
      • Miami, Florida, Vereinigte Staaten, 33136
        • UM Department Of Neurology
      • Miami, Florida, Vereinigte Staaten, 33133
        • Gables Neurology
      • Naples, Florida, Vereinigte Staaten, 34105
        • Aqualane Clinical Research
      • Orlando, Florida, Vereinigte Staaten, 32803
        • Advent Health Orlando
      • Pembroke Pines, Florida, Vereinigte Staaten, 33024
        • Humanity Clinical Research
      • Pensacola, Florida, Vereinigte Staaten, 32514
        • Emerald Coast Neurology
      • Port Orange, Florida, Vereinigte Staaten, 32127
        • Brain and Spine Institute
      • Vero Beach, Florida, Vereinigte Staaten, 32960
        • Vero Beach Neurology
      • Winter Park, Florida, Vereinigte Staaten, 32789
        • Conquest Research
    • Indiana
      • Merrillville, Indiana, Vereinigte Staaten, 46410
        • Methodist Neuroscience Institute
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • University of Kansas Hospital
    • Kentucky
      • Nicholasville, Kentucky, Vereinigte Staaten, 40356
        • Baptist Physicians Lexington
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70121
        • Ochsner Clinic Foundation
    • Maryland
      • Frederick, Maryland, Vereinigte Staaten, 21702
        • Clinre Comprehensive Neurology
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02111
        • Tufts Medical Center
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64128
        • Kansas City VA Medical Center
    • New York
      • Patchogue, New York, Vereinigte Staaten, 11772
        • South Shore Neurologic Associates
    • North Carolina
      • Chapel Hill, North Carolina, Vereinigte Staaten, 27599-9500
        • University Of NC At Chapel Hill
      • Charlotte, North Carolina, Vereinigte Staaten, 28210
        • Piedmont HealthCare
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43235
        • The Boster Ctr for MS
      • Dayton, Ohio, Vereinigte Staaten, 45408
        • Neurology Diagnostics Inc
    • Pennsylvania
      • Hershey, Pennsylvania, Vereinigte Staaten, 17033
        • Penn State Hershey Medical Center
    • South Carolina
      • Greenville, South Carolina, Vereinigte Staaten, 29605
        • Premier Neurology
      • Old Point Station, South Carolina, Vereinigte Staaten, 29707
        • Metrolina Neurological Associates PA
    • Tennessee
      • Knoxville, Tennessee, Vereinigte Staaten, 37922
        • Sibyl Wray MD Neurology PC
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75231
        • Carum Research
      • El Paso, Texas, Vereinigte Staaten, 79935
        • Med Research Inc
      • Frisco, Texas, Vereinigte Staaten, 75035
        • Lone Star Neurology
      • San Antonio, Texas, Vereinigte Staaten, 78258
        • Lonestar Neurology of San Antonio
      • San Antonio, Texas, Vereinigte Staaten, 78229
        • UT Health MARC Medical Arts and Research Center
      • Sherman, Texas, Vereinigte Staaten, 75092
        • Texas Institute for Neurological Disorders
      • Temple, Texas, Vereinigte Staaten, 76508
        • Baylor Scott and White
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98101
        • Virginia Mason Medical Centre
      • Seattle, Washington, Vereinigte Staaten, 98133
        • University of Washington MS Clinic
    • West Virginia
      • Crab Orchard, West Virginia, Vereinigte Staaten, 25827
        • Elligo Health Research
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53215
        • Ascension St Francis Center
    • Invernesshire
      • Inverness, Invernesshire, Vereinigtes Königreich, IV2 3RE
        • Novartis Investigative Site
    • Kent
      • Canterbury, Kent, Vereinigtes Königreich, CT1 3NG
        • Novartis Investigative Site

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 55 Jahre (Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • 18 to 55 years of age
  • Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
  • At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
  • EDSS score of 0 to 5.5 (inclusive)
  • Neurologically stable within 1 month

Exclusion Criteria:

  • Diagnosis of primary progressive multiple sclerosis (PPMS)

  • Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening

  • History of clinically significant CNS disease other than MS

  • Ongoing substance abuse (drug or alcohol)

  • History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),

  • Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML

  • suicidal ideation or behavior

  • Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence

  • Participants who have had a splenectomy

  • Active clinically significant systemic bacterial, viral, parasitic or fungal infections

  • Positive results for syphilis or tuberculosis testing

  • Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids

  • Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.

  • Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody

  • History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.

  • History of severe renal disease or creatinine level

  • Participants at risk of developing or having reactivation of hepatitis

  • Hematology parameters at screening:

    • Hemoglobin: < 10 g/dl (<100g/L)
    • Platelets: < 100000/mm3 (<100 x 109/L)
    • Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
    • White blood cells: <3 000/mm3 (<3.0 x 109/L)
    • Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
    • B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
  • History or current diagnosis of significant ECG abnormalities

  • Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit

  • Use of other investigational drugs

  • Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,

  • History of gastrointestinal bleeding

  • Major surgery within 8 weeks prior to screening

  • History of hypersensitivity to any of the study drugs or excipients

  • Pregnant or nursing (lactating) female participants, prior to randomization

  • Women of childbearing potential not using highly effective contraception

  • Sexually active males not agreeing to use condom

  • Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study

  • Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization

Inclusion to Extension part:

• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)

Other inclusion and exclusion criteria may apply.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Remibrutinib - Core

Remibrutinib tablet and matching placebo of teriflunomide capsule

tablet taken orally

Andere Namen:
  • LOU064
Aktiver Komparator: Teriflunomide - Core

Teriflunomide capsule and matching placebo remibrutinib tablet

capsule taken orally

Experimental: Remibrutinib - Extension

Participants on remibrutinib in Core will continue on remibrutinib tablet

tablet taken orally

Andere Namen:
  • LOU064
Experimental: Remibrutinib - Extension (on teriflunomide in Core)

Participants on teriflunomide in Core will switch to remibrutinib tablet

tablet taken orally

Andere Namen:
  • LOU064

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Zeitfenster: From Baseline, up to 30 months

ARR is the average number of confirmed MS relapses in a year

From Baseline, up to 30 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months

Baseline up to 30 months
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Annualized rate of new or enlarging T2 lesion [Core Part]
Zeitfenster: Baseline up to 30 months

Number of new/newly enlarged T2 lesions per year

Baseline up to 30 months
Neurofilament light chain (Nfl) [Core Part]
Zeitfenster: Baseline up to 30 months

Neurofilament light chain (NfL) concentration in serum

Baseline up to 30 months
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Zeitfenster: Baseline up to 30 months

Average number of Gd-enhancing T1 lesions per scan

Baseline up to 30 months
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI

Baseline up to 30 months
Time to first confirmed relapse [Core Part]
Zeitfenster: Baseline up to 30 months

Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating.

Baseline up to 30 months
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months

Baseline up to 30 months
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve

Baseline up to 30 months
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Baseline up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Zeitfenster: Baseline, up to 30 months

The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score

Baseline, up to 30 months
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand)

Baseline up to 30 months
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Zeitfenster: Baseline up to 30 months

The composite involves CDP and worsening by at least 20% in T25FW and 9HPT

Baseline up to 30 months
Change from Baseline in T2 lesion volume [Core Part]
Zeitfenster: Baseline up to 30 months

Change from baseline in total T2 lesion volume.

Baseline up to 30 months
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Zeitfenster: Baseline up to 30 months

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Baseline up to 30 months
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Zeitfenster: Baseline up to 30 months

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Baseline up to 30 months
Pharmacokinetics of remibrutinib [Core Part]
Zeitfenster: Month 1, Month 6

Blood concentrations of remibrutinib

Month 1, Month 6
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating

Day 1 Extension up to 5 years
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

ARR is the average number of confirmed MS relapses in a year

Day 1 Extension up to 5 years
Annualized rate of new or enlarging T2 lesion [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

Number of new/newly enlarged T2 lesions per year

Day 1 Extension up to 5 years
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months

Day 1 Extension up to 5 years
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening

Day 1 Extension up to 5 years
Neurofilament light chain (NfL) [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

Neurofilament light chain (NfL) concentration in serum

Day 1 Extension up to 5 years
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Zeitfenster: Day 1 Extension up to 5 years

29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life

Day 1 Extension up to 5 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. Dezember 2021

Primärer Abschluss (Tatsächlich)

22. Juli 2026

Studienabschluss (Geschätzt)

30. Oktober 2030

Studienanmeldedaten

Zuerst eingereicht

1. Dezember 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

1. Dezember 2021

Zuerst gepostet (Tatsächlich)

14. Dezember 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CLOU064C12302
  • 2023-509372-41-00 (Registrierungskennung: EU CTIS)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .